Incidence of Catheter-Related Thrombosis in Patients with Long-Term Indwelling Central Venous Port Who Received Chemotherapies for Unresectable Advanced Digestive Cancers

• Published in: Gan to kagaku ryoho Vol. 46; no. 13; p. 2182
• Main Authors: Tanioka, Hiroaki, Asano, Motoi, Kawasaki, Kento, Yoshida, Ryosuke, Waki, Naohisa, Uno, Futoshi, Ishizaki, Masahiro, Yamashita, Kazuki, Katata, Yosuke, Sano, Fuminori, Okawaki, Makoto, Yamamura, Masahiro, Nagasaka, Takeshi, Yamaguchi, Yoshiyuki
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.12.2019
• Subjects: Catheterization, Central Venous; Catheters, Indwelling - adverse effects; Digestive System Neoplasms - drug therapy; Humans; Incidence; Retrospective Studies; Thrombosis - etiology; Time Factors
• ISSN: 0385-0684

Most patients with unresectable advanced digestive cancers require placement of a fully implantable venous access port to facilitate safe delivery of anti-cancer drugs. Anti-VEGF therapies are commonly used even though they increase the risk of thrombosis. The objective of this study was to assess the incidence of radiologically confirmed catheter-related thrombosis(CRT)in patients with advanced digestive cancers. We retrospectively reviewed 88 patients with advanced digestive cancers who had adapted implantable ports placed in our institution for chemotherapy. Thirty-nine patients were diagnosed with colorectal cancer, 26 with gastric cancer, 12 with pancreatic cancer, 8 with esophageal cancer, and 3 with other cancers. During follow-up, 22 patients(25%)received anti-VEGF therapies, while 66 patients(75%)did not. Four out of 88 patients(4.5%)had asymptomatic CRT. The incidence of CRT was the same(4.5%)regardless of whether the patient received anti-VEGF therapy. In patients with digestive cancers who had implantable venous access ports, the incidence of the CRT was 4.5% with no association with anti-VEGF therapies.